Navigation Links
Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals' Lorcaserin Achieved Statistically Significant Weight Loss
Date:5/26/2011

meters."

The three lorcaserin Phase 3 trials randomized a total of 7,794 patients, and 7,500 patients were included in the primary efficacy analyses (MITT-LOCF), which required a patient to have taken at least one dose of study medication and have had at least one weight measurement subsequent to baseline. The MITT-LOCF analyses included 3,349 lorcaserin 10 mg BID patients, 865 lorcaserin 10 mg QD patients and 3,286 placebo patients. Patients had an average BMI, baseline weight and age of approximately 36 kg/m2, 100 kg and 45 years, respectively; approximately 80% of patients were female.

About LorcaserinLorcaserin is an investigational drug candidate intended for weight management, including weight loss and maintenance of weight loss, in patients who are obese (BMI >30) or patients who are overweight (BMI >27) and have at least one weight-related co-morbid condition. Lorcaserin is a new chemical entity that is believed to act as a selective serotonin 2C receptor agonist. The serotonin 2C receptor is expressed in the brain, including the hypothalamus, an area believed to be involved in the control of appetite and metabolism. Arena has patents that cover lorcaserin in the United States and other jurisdictions that in most cases are capable of continuing into 2023 without taking into account any patent term extensions or other exclusivity Arena might obtain.

Arena submitted a New Drug Application (NDA) for lorcaserin to the US Food and Drug Administration (FDA) in December 2009, and the FDA issued a Complete Response Letter (CRL) in October 2010. Arena is engaged in activities to address the issues raised by the FDA as part of its plan to submit a response to the CRL.

Lorcaserin Phase 3 Clinical Trial Program OverviewThe lorcaserin Phase 3 clinical trial program consists of three double-blind, randomized, placebo-controlled trials, BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management), BLOSSOM (
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pivotal Phase 3 Study Published in The New England Journal of Medicine (NEJM) Finds Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer is Significantly Improved with ZYTIGA™ (abiraterone acetate)
2. Ardea Biosciences Provides Additional Results From a Phase 2b Study of Lesinurad in Combination With Allopurinol at the Annual European Congress of Rheumatology
3. InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
4. Sinovac Reports Positive Phase I Clinical Trial Results for EV71 Vaccine Candidate Against Hand, Foot & Mouth Disease(HFMD)
5. KemPharm, Inc. Announces Positive Results from Phase 1 Trial of KP201 for Pain
6. Onyx Pharmaceuticals Announces Updated Pivotal Carfilzomib Phase 2B Data
7. ViroPharma Initiates Phase 2 Study of VP 20621 for Prevention of Recurrence of Clostridium difficile Infection (CDI)
8. Families of Spinal Muscular Atrophy Announces Repligen Corporation Receives FDA Approval to Begin Phase I Clinical Trial in SMA
9. EntreMed ENMD-2076 Phase 2 Data to Be Presented at ASCO Annual Meeting
10. Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting
11. Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014 Integrated Silicon Solution, ... advanced memory and analog IC solutions, today announced that ... July 24, 2014, at 7:00 a.m. Pacific Time (10:00 ... for the fiscal 2014 third quarter ended June 30, ... telephone, dial 1-888-556-4997 before 6:50 a.m. Pacific time on ...
(Date:7/10/2014)... , July 10, 2014  Valeant Pharmaceuticals International, Inc. ... announced it has completed the sale to Galderma of ... owned or held by Valeant for $1.4 billion in ... S.A, which recently completed its acquisition of Galderma. ... of our products to a company that is firmly ...
(Date:7/10/2014)... WOONSOCKET, R.I. , July 10, 2014 CVS ... its board of directors has approved a quarterly dividend of ... The dividend is payable on August 1, 2014, to holders ... Caremark CVS Caremark is dedicated to helping ... integrated pharmacy company in the United States ...
Breaking Medicine Technology:
(Date:7/11/2014)... surgery to repair damage to the anterior cruciate ligament (ACL) ... -- could increase a young athlete,s risk for further injuries, ... patients, aged 8 to 16, who had ACL reconstruction surgery. ... after their injury, 37 had surgery six to 12 weeks ... after their injury. The youngsters who had surgery later ...
(Date:7/11/2014)... CA (PRWEB) July 11, 2014 Ticket ... Bryan Tickets at the Sleep Train Amphitheatre in Wheatland, ... venues that can compare to what the Sleep Train Amphitheatre ... musical events and special attractions over the course of its ... 16th, the Sleep Train Amphitheatre in Wheatland (Sacramento metro area) ...
(Date:7/11/2014)... The “Proteomics Market by Technology (Protein Microarray, Mass ... X-ray Crystallography) - Instruments, Reagents & Services - ... major market drivers, restraints, and opportunities in North ... World (RoW). , The proteomics market has experienced ... due to the increasing need of proteomic outcomes ...
(Date:7/11/2014)... who screened positive for a history of hazardous or ... 50 percent after receiving mobile phone text messages following ... study published online yesterday in Annals of Emergency ... Young Adult Emergency Department Patients: A Randomized Clinical Trial ... 50,000 adults ages 18 to 24 visit ERs and ...
(Date:7/11/2014)... By Steven Reinberg ... -- Stress, hostility and depression may increase the risk for ... depression seemed to raise the risk of a stroke or ... also found that stress apparently raised stroke or TIA risk ... said. A TIA is a mini-stroke caused by a temporary ...
Breaking Medicine News(10 mins):Health News:Delaying Kid's Knee Surgery Could Be a Bad Play, Study Finds 2Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 2Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 3Health News:Proteomics Market Worth $20,696.4 Million by 2018 - New Report By MarketsandMarkets 2Health News:Proteomics Market Worth $20,696.4 Million by 2018 - New Report By MarketsandMarkets 3Health News:Proteomics Market Worth $20,696.4 Million by 2018 - New Report By MarketsandMarkets 4Health News:Text message medicine: Texts from the ER can reduce binge drinking 2Health News:Stress, Depression May Boost Stroke Risk, Study Finds 2Health News:Stress, Depression May Boost Stroke Risk, Study Finds 3
... SCHAUMBURG, Ill., May 12 For the estimated ... important fashion accessory,that many women wear, and change, daily. ... more than they bargained for when purchasing,inexpensive earrings. Nickel ... on the earlobes and repeated exposure can make treatment,difficult., ...
... investigation after efforts uncover ... system abuse, ... New York State in 2007. With so many recipients and,providers involved, the ... fraud, waste, and abuse., Over the last two years, Salient Corporation, ...
... for event -, MCLEAN, Va., May 12 ... more effective than real, live dogs or cats ... other aging-related,illnesses?, Come find out Monday, June ... Community (VHRC) in McLean, Va., hosts an industry ...
... its,Distinguished Americans series, the U.S. Postal Service released ... Edward Livingston Trudeau (1848-1915), the,founder and first president ... of Tuberculosis, the precursor to the American Lung ... treating tuberculosis, a,highly infectious disease that at one ...
... Indoor Air Professionals advises consumers on indoor air quality, ... Asthma Awareness Month,according the Environmental Protection Agency (EPA), and ... consumers on the,importance of clean indoor air in relation ... nearly 2 million Americans to the emergency,room in the ...
... earn both national, ... state kudos, SOUTHFIELD, Mich., May 12 ... Care Network of,Michigan., BCN is one of 20 companies worldwide receiving the ... the second year,in a row BCN has earned the annual award. On May ...
Cached Medicine News:Health News:Study Finds Nearly One-Third of All Inexpensive Earrings Examined Tested Positive for Nickel 2Health News:Study Finds Nearly One-Third of All Inexpensive Earrings Examined Tested Positive for Nickel 3Health News:Study Finds Nearly One-Third of All Inexpensive Earrings Examined Tested Positive for Nickel 4Health News:Salient Corporation's Performance Management Solution Helps NY State Counties Identify Medicaid Fraud, Waste, and Abuse 2Health News:Paro, the World's Only Robotic Baby Harp Seal - Designed Specifically for Therapy - to be Focus of Industry Event at Vinson Hall Retirement Community in McLean, Va., June 2 2Health News:American Lung Association Founder Honored With New U.S. Postage Stamp 2Health News:Asthma Awareness Month Spawns Healthy Advice 2Health News:Blue Care Network of Michigan Named a Great Workplace by Gallup, MBPA 2Health News:Blue Care Network of Michigan Named a Great Workplace by Gallup, MBPA 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... used in the ARED study, as well ... which suggested no AMD disease progression in ... period. Macula Complete also contains efficacious amounts ... support the mitochondria, as well as to ...
... MacularProtect delivers levels of ... vision and macular health in ... by The National Eye Institute. ... of lutein, an antioxidant found ...
... is a scientifically advanced nutritional formulation ... and full body health. MacularProtect Complete ... trial and other advanced research. It ... provides a broad foundation of antioxidants, ...
Medicine Products: